8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Mar 12, 2026·SEC
Precision BioSciences, Inc.(DTIL)Earnings, Financials & Key Ratios
DTIL•NASDAQ
$7.48
$96M mkt cap·Price updated May 7, 2026
AboutPrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Show more
- Revenue$34M-50.1%
- EBITDA-$49M-128.8%
- Net Income-$47M-750.3%
- EPS (Diluted)-3.63-449.0%
- Gross Margin91.97%-8.0%
- EBITDA Margin-144.16%-358.8%
- Operating Margin-152.19%-299.6%
- Net Margin-136.03%-1403.8%
- ROE-62.71%-429.2%
- ROIC-726.16%
- Debt/Equity0.31-41.4%
- Interest Coverage-36.67-830.2%
DTIL Key Insights
Precision BioSciences, Inc. (DTIL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 15.6%
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 86.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
DTIL Price & Volume
Precision BioSciences, Inc. (DTIL) stock price & volume — 10-year historical chart
Loading chart...
DTIL Growth Metrics
Precision BioSciences, Inc. (DTIL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years7.13%
3 Years10.93%
TTM-11.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-102.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-56.96%
Return on Capital
10 Years-36.65%
5 Years-31.02%
3 Years-30.68%
Last Year-39.08%
DTIL Recent Earnings
Precision BioSciences, Inc. (DTIL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026EPS
$0.75
Est $0.66
-14.5%
Revenue
$11M
Est $4M
+167.6%
Q2 2026
Mar 12, 2026EPS
$0.36
Est $0.21
+271.4%
Revenue
$34M
Est $9M
+276.9%
Q4 2025
Nov 3, 2025EPS
$1.84
Est $0.31
-493.5%
Revenue
$13,000
Est $9M
-99.9%
Q3 2025
Aug 7, 2025EPS
$2.13
Est $0.09
-2266.7%
Revenue
$18,000
Est $5M
-99.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.75vs $0.66-14.5% | $11Mvs $4M+167.6% |
| Q2 2026 | Mar 12, 2026 | $0.36vs $0.21+271.4% | $34Mvs $9M+276.9% |
| Q4 2025 | Nov 3, 2025 | $1.84vs $0.31-493.5% | $13,000vs $9M-99.9% |
| Q3 2025 | Aug 7, 2025 | $2.13vs $0.09-2266.7% | $18,000vs $5M-99.7% |
Based on last 12 quarters of dataView full earnings history →
DTIL Peer Comparison
Precision BioSciences, Inc. (DTIL) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 SANA | 917.92M | 3.50 | -3.02 | -120.02% | 0.38 | |||
 ALLO | 520.77M | 2.27 | -2.61 | -100% | -57.07% | 0.26 | ||
 PGEN | 1.22B | 4.15 | -8.83 | -36.95% | -39.13% | -5.9% | 0.14 |
Compare DTIL vs Peers
Precision BioSciences, Inc. (DTIL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DTIL Income Statement
Precision BioSciences, Inc. (DTIL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.48M | 10.88M | 22.24M | 24.29M | 115.53M | 25.1M | 48.73M | 68.7M | 34.26M | 45.07M |
| Revenue Growth % | -7.57% | 67.84% | 104.34% | 9.21% | 375.72% | -78.28% | 94.15% | 40.98% | -50.12% | -11.87% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.75M | 1.37M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 8.03% | - |
| Gross Profit | 6.48M▲ 0% | 10.88M▲ 67.8% | 22.24M▲ 104.3% | 24.29M▲ 9.2% | 115.53M▲ 375.7% | 25.1M▼ 78.3% | 48.73M▲ 94.1% | 68.7M▲ 41.0% | 31.51M▼ 54.1% | 43.7M▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 91.97% | 96.95% |
| Gross Profit Growth % | -7.57% | 67.84% | 104.34% | 9.21% | 375.72% | -78.28% | 94.15% | 40.98% | -54.13% | - |
| Operating Expenses | 28.34M | 58.8M | 109.44M | 134.11M | 154.91M | 87.41M | 92.46M | 94.86M | 83.66M | 82.81M |
| OpEx % of Revenue | 437.08% | 540.25% | 492.14% | 552.25% | 134.08% | 348.26% | 189.76% | 138.08% | 244.16% | - |
| Selling, General & Admin | 8.02M | 13.67M | 27.03M | 36.05M | 39.67M | 41.28M | 39.09M | 35.3M | 32.24M | 30.49M |
| SG&A % of Revenue | 123.63% | 125.64% | 121.53% | 148.45% | 34.34% | 164.49% | 80.22% | 51.38% | 94.09% | - |
| Research & Development | 20.32M | 45.12M | 82.42M | 98.06M | 115.24M | 46.12M | 53.38M | 59.56M | 54.17M | 53.36M |
| R&D % of Revenue | 313.45% | 414.61% | 370.61% | 403.79% | 99.75% | 183.77% | 109.54% | 86.7% | 158.1% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.75M | -1.04M |
| Operating Income | -21.97M▲ 0% | -47.91M▼ 118.0% | -87.2M▼ 82.0% | -109.83M▼ 25.9% | -39.38M▲ 64.1% | -62.31M▼ 58.2% | -43.74M▲ 29.8% | -26.16M▲ 40.2% | -52.15M▼ 99.3% | -39.11M▲ 0% |
| Operating Margin % | -338.9% | -440.25% | -392.14% | -452.25% | -34.08% | -248.26% | -89.76% | -38.08% | -152.19% | -86.77% |
| Operating Income Growth % | -148.91% | -118.04% | -82.01% | -25.94% | 64.15% | -58.24% | 29.81% | 40.18% | -99.33% | - |
| EBITDA | -20.54M | -45.56M | -81.89M | -100.02M | -29.18M | -53.3M | -35.48M | -21.59M | -49.4M | -36.42M |
| EBITDA Margin % | -316.76% | -418.62% | -368.23% | -411.84% | -25.26% | -212.38% | -72.82% | -31.42% | -144.16% | -80.81% |
| EBITDA Growth % | -150.84% | -121.81% | -79.74% | -22.14% | 70.83% | -82.68% | 33.44% | 39.16% | -128.84% | 9.47% |
| D&A (Non-Cash Add-back) | 1.44M | 2.35M | 5.32M | 9.81M | 10.2M | 9M | 8.26M | 4.58M | 2.75M | 2.69M |
| EBIT | -21.86M | -46.04M | -92.69M | -109.01M | -30.47M | -71.8M | -40.3M | 8.95M | -52.15M | -34.05M |
| Net Interest Income | 872K | 1.88M | 4.08M | 822K | 76K | 2.36M | 5.46M | 4.98M | 2.82M | 2.54M |
| Interest Income | 872K | 1.88M | 4.27M | 822K | 208K | 3.47M | 7.69M | 6.76M | 4.24M | 3.92M |
| Interest Expense | 0 | 0 | 182K | 0 | 132K | 1.11M | 2.23M | 1.78M | 1.42M | 1.38M |
| Other Income/Expense | 872K | 1.88M | -5.67M | 822K | 8.77M | -10.6M | 1.21M | 33.33M | 5.54M | -5.37M |
| Pretax Income | -21.1M▲ 0% | -46.04M▼ 118.2% | -92.88M▼ 101.7% | -109.01M▼ 17.4% | -30.6M▲ 71.9% | -72.91M▼ 138.2% | -42.53M▲ 41.7% | 7.17M▲ 116.9% | -46.61M▼ 750.3% | -44.48M▲ 0% |
| Pretax Margin % | -325.45% | -423.02% | -417.65% | -448.86% | -26.49% | -290.5% | -87.28% | 10.43% | -136.03% | -98.7% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -21.1M▲ 0% | -46.04M▼ 118.2% | -92.88M▼ 101.7% | -109.01M▼ 17.4% | -30.6M▲ 71.9% | -111.64M▼ 264.8% | -61.32M▲ 45.1% | 7.17M▲ 111.7% | -46.61M▼ 750.3% | -44.48M▲ 0% |
| Net Margin % | -325.45% | -423.02% | -417.65% | -448.86% | -26.49% | -444.8% | -125.84% | 10.43% | -136.03% | -98.7% |
| Net Income Growth % | -155.75% | -118.16% | -101.74% | -17.37% | 71.93% | -264.8% | 45.07% | 111.69% | -750.33% | -102.33% |
| Net Income (Continuing) | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -72.91M | -42.53M | 7.17M | -46.61M | -44.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -38.73M | -18.79M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -18.81▲ 0% | -28.17▼ 49.8% | -59.50▼ 111.2% | -62.85▼ 5.6% | -15.60▲ 75.2% | -38.10▼ 144.2% | -15.96▲ 58.1% | 1.04▲ 106.5% | -3.63▼ 449.0% | -1.81▲ 0% |
| EPS Growth % | -3738.78% | -49.76% | -111.22% | -5.63% | 75.18% | -144.23% | 58.11% | 106.52% | -449.04% | -56.96% |
| EPS (Basic) | -18.81 | -28.17 | -59.50 | -62.85 | -15.60 | -38.10 | -15.96 | 1.05 | -3.63 | - |
| Diluted Shares Outstanding | 1.12M | 1.63M | 1.4M | 1.73M | 1.96M | 2.93M | 3.84M | 6.88M | 12.83M | 24.63M |
| Basic Shares Outstanding | 1.12M | 1.63M | 1.4M | 1.73M | 1.96M | 2.93M | 3.84M | 6.83M | 12.83M | 24.63M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DTIL Balance Sheet
Precision BioSciences, Inc. (DTIL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 64.33M | 115.67M | 193.67M | 105.56M | 161.75M | 199.1M | 136.36M | 94.99M | 118.74M | 108.69M |
| Cash & Short-Term Investments | 62.8M | 103.19M | 180.89M | 89.8M | 143.66M | 189.58M | 116.68M | 86.31M | 115.58M | 101.18M |
| Cash Only | 62.8M | 103.19M | 180.89M | 89.8M | 143.66M | 189.58M | 116.68M | 85.9M | 110.82M | 99.37M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 413K | 4.76M | 1.81M |
| Accounts Receivable | 22K | 523K | 965K | 10M | 488K | 720K | 12.8M | 1.7M | 0 | 4M |
| Days Sales Outstanding | 1.24 | 17.54 | 15.84 | 150.3 | 1.54 | 10.47 | 95.87 | 9.02 | - | 8.11 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 70K | 3.05M | 2.32M | 4K | 169K | 2.78M | 906K | 538K | 3.15M | 3.51M |
| Total Non-Current Assets | 8.35M | 22.93M | 41.56M | 44.59M | 49.74M | 39.06M | 23.42M | 41.4M | 35.68M | 35.2M |
| Property, Plant & Equipment | 8.14M | 21.15M | 39.57M | 41.5M | 29.33M | 13.78M | 14.6M | 10.18M | 7.23M | 6.65M |
| Fixed Asset Turnover | 0.80x | 0.51x | 0.56x | 0.59x | 3.94x | 1.82x | 3.34x | 6.75x | 4.74x | 7.63x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 90K | 1.47M | 1.43M | 1.37M | 2.05M | 731K | 400K | 622K | 1.17M | 1.13M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 6.84M | 4.75M | 3.21M | 3.21M | 744K | 34.69M |
| Other Non-Current Assets | 124K | 312K | 558K | 1.72M | 11.52M | 19.81M | 5.21M | 27.39M | 26.54M | 89.15M |
| Total Assets | 72.68M▲ 0% | 138.6M▲ 90.7% | 235.23M▲ 69.7% | 150.16M▼ 36.2% | 211.5M▲ 40.9% | 238.17M▲ 12.6% | 159.78M▼ 32.9% | 136.39M▼ 14.6% | 154.42M▲ 13.2% | 143.89M▲ 0% |
| Asset Turnover | 0.09x | 0.08x | 0.09x | 0.16x | 0.55x | 0.11x | 0.30x | 0.50x | 0.22x | 0.36x |
| Asset Growth % | -26.15% | 90.69% | 69.72% | -36.17% | 40.85% | 12.61% | -32.91% | -14.64% | 13.22% | -44.41% |
| Total Current Liabilities | 9.2M | 14.07M | 26.93M | 42.83M | 35.98M | 59.66M | 49.99M | 14.98M | 8.91M | 7.75M |
| Accounts Payable | 1.81M | 2.22M | 2.04M | 792K | 1.14M | 653K | 2.97M | 1.31M | 296K | 944K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | 39.24 | 245.79 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 22.41M | 0 | 1.51M | 1.56M |
| Deferred Revenue (Current) | 5.82M | 8.44M | 16.49M | 30.24M | 21.24M | 46.19M | 12.04M | 2.96M | 0 | 12.24M |
| Other Current Liabilities | 590K | 2.46M | 6.01M | 6.6M | 7.74M | 9.31M | 9.88M | 7.38M | 7.11M | 5.25M |
| Current Ratio | 6.99x | 8.22x | 7.19x | 2.46x | 4.50x | 3.34x | 2.73x | 6.34x | 13.32x | 13.32x |
| Quick Ratio | 6.99x | 8.22x | 7.19x | 2.46x | 4.50x | 3.34x | 2.73x | 6.34x | 13.32x | 13.32x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -237.68 |
| Total Non-Current Liabilities | 89.85M | 84.56M | 69.99M | 62.9M | 84.35M | 118.07M | 90.93M | 65.02M | 53.26M | 60.03M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 2.48M | 22.22M | 0 | 22.32M | 22.4M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 8.59M | 4.81M | 1.06M | 7.72M | 6.4M | 4.9M | 15.87M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.25M | 1.76M | 4.09M | 392K | 44K | 1.92M | 128K | 2.99M | 15.95M | 83.29M |
| Total Liabilities | 99.05M | 98.64M | 96.92M | 105.73M | 120.33M | 177.74M | 140.92M | 80M | 62.17M | 67.79M |
| Total Debt | 0 | 0 | 0 | 10.52M | 9.11M | 24.96M | 31.27M | 30.05M | 28.81M | 1.56M |
| Net Debt | -62.8M | -103.19M | -180.89M | -79.28M | -134.55M | -164.62M | -85.41M | -55.85M | -82.02M | -97.81M |
| Debt / Equity | - | - | - | 0.24x | 0.10x | 0.41x | 1.66x | 0.53x | 0.31x | 0.31x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.69x |
| Interest Coverage | - | - | -509.31x | - | -230.83x | -64.62x | -18.07x | 5.02x | -36.67x | -24.69x |
| Total Equity | -26.37M▲ 0% | 39.96M▲ 251.5% | 138.31M▲ 246.1% | 44.42M▼ 67.9% | 91.17M▲ 105.2% | 60.43M▼ 33.7% | 18.86M▼ 68.8% | 56.39M▲ 199.0% | 92.25M▲ 63.6% | 76.1M▲ 0% |
| Equity Growth % | -455.25% | 251.54% | 246.13% | -67.88% | 105.22% | -33.71% | -68.79% | 198.99% | 63.58% | -10.95% |
| Book Value per Share | -23.51 | 24.45 | 98.80 | 25.61 | 46.60 | 20.63 | 4.91 | 8.19 | 7.19 | 3.09 |
| Total Shareholders' Equity | -26.37M | 39.96M | 138.31M | 44.42M | 91.17M | 60.43M | 18.86M | 56.39M | 92.25M | 76.1M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -39.11M | -85.19M | -177.07M | -286.07M | -316.68M | -428.31M | -489.63M | -482.46M | -528.19M | -546.63M |
| Treasury Stock | -952K | -952K | -952K | -952K | -952K | -952K | -952K | -952K | -952K | 0 |
| Accumulated OCI | -3.19M | -5.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DTIL Cash Flow Statement
Precision BioSciences, Inc. (DTIL) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -24.17M | -51.72M | -73.64M | -87.39M | -10.85M | -45.75M | -84.11M | -58.45M | -65.84M | -65.84M |
| Operating CF Margin % | -372.75% | -475.26% | -331.13% | -359.84% | -9.39% | -182.3% | -172.62% | -85.08% | -192.16% | - |
| Operating CF Growth % | -126.19% | -114.01% | -42.37% | -18.67% | 87.58% | -321.57% | -83.84% | 30.52% | -12.66% | -117.49% |
| Net Income | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -111.64M | -61.32M | 7.17M | -45.72M | -44.48M |
| Depreciation & Amortization | 1.44M | 2.35M | 5.32M | 9.81M | 10.2M | 9M | 8.26M | 4.58M | 2.75M | 2.69M |
| Stock-Based Compensation | 419K | 2.45M | 0 | 13.79M | 16.51M | 19.2M | 14.04M | 12.6M | 10.19M | 8.91M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 174K | 14K | 16.28M | 35K | -26.55M | 13.57M | -3.6M | -28.79M | -8.35M | -3.78M |
| Working Capital Changes | -5.09M | -10.51M | -2.36M | -2.01M | 19.58M | 24.11M | -41.49M | -54M | -24.71M | -22.95M |
| Change in Receivables | 0 | -523K | -441K | -9.04M | 9.51M | -232K | -181K | 10.42M | 229K | -5.46M |
| Change in Inventory | 0 | -5.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 864K | -673K | 667K | -1.46M | 867K | 153K | 1.51M | -2.1M | -737K | 17K |
| Cash from Investing | -5.51M | -15.66M | -24.67M | -5.03M | -5.8M | -3.32M | 5.83M | -215K | -634K | -434K |
| Capital Expenditures | -5.57M | -15.68M | -24.67M | -5.03M | -5.05M | -3.32M | -2.28M | -250K | -85K | -69K |
| CapEx % of Revenue | 85.83% | 144.06% | 110.92% | 20.72% | 4.37% | 13.22% | 4.67% | 0.36% | 0.25% | - |
| Acquisitions | 50K | 15K | 0 | 0 | 0 | 0 | 8M | 60K | 0 | 27K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 50K | 15K | 0 | 0 | -750K | 0 | 107K | -25K | -549K | -392K |
| Cash from Financing | -937K | 107.78M | 176M | 1.33M | 70.52M | 94.98M | 5.39M | 50.45M | 95.16M | 85.22M |
| Debt Issued (Net) | 0 | 0 | 39.55M | 0 | 2.47M | 19.8M | 0 | -37K | 0 | 0 |
| Equity Issued (Net) | -952K | 109.74M | 136.45M | 0 | 60.48M | 74.34M | 4.99M | 50.24M | 95.16M | 84.47M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -952K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 15K | -1.97M | 0 | 1.33M | 7.57M | 835K | 401K | 249K | 0 | 745K |
| Net Change in Cash | -30.62M▲ 0% | 40.39M▲ 231.9% | 77.69M▲ 92.4% | -91.09M▼ 217.2% | 53.87M▲ 159.1% | 45.91M▼ 14.8% | -72.9M▼ 258.8% | -8.21M▲ 88.7% | 28.68M▲ 449.4% | 22.28M▲ 0% |
| Free Cash Flow | -29.73M▲ 0% | -67.4M▼ 126.7% | -98.3M▼ 45.8% | -92.42M▲ 6.0% | -16.66M▲ 82.0% | -49.07M▼ 194.6% | -86.39M▼ 76.1% | -58.7M▲ 32.1% | -65.93M▼ 12.3% | -58.78M▲ 0% |
| FCF Margin % | -458.57% | -619.32% | -442.05% | -380.55% | -14.42% | -195.52% | -177.3% | -85.44% | -192.41% | -130.42% |
| FCF Growth % | -132.96% | -126.68% | -45.85% | 5.99% | 81.98% | -194.62% | -76.05% | 32.06% | -12.32% | 0.4% |
| FCF per Share | -26.51 | -41.24 | -70.22 | -53.28 | -8.51 | -16.75 | -22.49 | -8.53 | -5.14 | -5.14 |
| FCF Conversion (FCF/Net Income) | 1.15x | 1.12x | 0.79x | 0.80x | 0.35x | 0.41x | 1.37x | -8.15x | 1.41x | 1.32x |
| Interest Paid | 0 | 0 | 0 | 0 | 68K | 824K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DTIL Key Ratios
Precision BioSciences, Inc. (DTIL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -677.46% | -104.2% | -119.3% | -45.14% | -147.28% | -154.66% | 19.05% | -62.71% | -81.24% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | -726.16% | -726.16% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 91.97% | 96.95% |
| Net Margin | -325.45% | -423.02% | -417.65% | -448.86% | -26.49% | -444.8% | -125.84% | 10.43% | -136.03% | -98.7% |
| Debt / Equity | - | - | - | 0.24x | 0.10x | 0.41x | 1.66x | 0.53x | 0.31x | 0.31x |
| Interest Coverage | - | - | -509.31x | - | -230.83x | -64.62x | -18.07x | 5.02x | -36.67x | -24.69x |
| FCF Conversion | 1.15x | 1.12x | 0.79x | 0.80x | 0.35x | 0.41x | 1.37x | -8.15x | 1.41x | 1.32x |
| Revenue Growth | -7.57% | 67.84% | 104.34% | 9.21% | 375.72% | -78.28% | 94.15% | 40.98% | -50.12% | -11.87% |
DTIL SEC Filings & Documents
Precision BioSciences, Inc. (DTIL) SEC filings — annual & quarterly reports (10-K, 10-Q)
DTIL Frequently Asked Questions
Precision BioSciences, Inc. (DTIL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Precision BioSciences, Inc. (DTIL) reported $45.1M in revenue for fiscal year 2025. This represents a 543% increase from $7.0M in 2016.
Precision BioSciences, Inc. (DTIL) saw revenue decline by 50.1% over the past year.
Precision BioSciences, Inc. (DTIL) reported a net loss of $44.5M for fiscal year 2025.
Dividend & Returns
Precision BioSciences, Inc. (DTIL) has a return on equity (ROE) of -62.7%. Negative ROE indicates the company is unprofitable.
Precision BioSciences, Inc. (DTIL) had negative free cash flow of $58.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More DTIL
Precision BioSciences, Inc. (DTIL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates